Women’s Healthcare Startup Juno Bio Raises $3.8M in Funding

The company will use the funding to expand its clinical testing capabilities, speed up partnerships with pharmaceutical companies, and increase the capacity of its new sequencing facility.

Juno Bio, a women's health company focused on precision vaginal microbiome testing and multi-omics, has opened its first sequencing laboratory dedicated entirely to women's health.

Read More:Deep Tech Startup Aina Raises $5.5M in Seed Funding

Since it was founded, Juno Bio has been helping improve women's vaginal health through advanced microbiome testing. The company has built one of the world's largest vaginal microbiome data collections and has helped thousands of women get more accurate testing and personalized care. More than 20,000 of its wellness tests have been sold through organic demand.

Juno Bio has since expanded into a broader clinical platform by growing its research and clinical capabilities. It now works with pharmaceutical companies on research, operates its own clinical laboratory, offers telehealth and pharmacy services, and is supported by a network of medical experts, including Dr. Anna Powell of Johns Hopkins, a specialist in reproductive infectious diseases and vulvovaginal disorders.

"Juno Bio is setting a new standard for how vaginal health is understood and managed," said Check Warner, Co-founding Partner at Ada Ventures. "What they've built at this stage with this level of capital efficiency, is exceptional. We're proud to support the team as they scale their clinical infrastructure and continue leading innovation in this critically underserved category."

"Over the past five years, Juno Bio has grown from a pioneering vaginal microbiome test into a clinical platform advancing a new standard of care for women's health," said Hana Janebdar, Founder and CEO of Juno Bio. "We've built one of the largest repositories of vaginal microbiome data, helped thousands of women access clearer answers, expanded our clinical and scientific infrastructure and deepened our partnerships across research and care delivery.

"The vaginal microbiome is still one of the least understood systems in the body at a clinical scale. With our lab, we're starting to build a measurement standard that clinicians can actually use," said Leighton Turner, PhD, Founder and CSO of Juno Bio. "We believe the level of detail from this kind of testing can meaningfully improve how vaginal healthcare is provided."

About Juno Bio

Founded by Leighton Turner and Hana Janebdar, Juno Bio is a women's health company focused on improving vaginal health through precision microbiome testing. Using advanced sequencing technology, the company provides personalized insights to help women better understand and manage their vaginal health. Juno Bio is also building a large health data platform to improve how vaginal health conditions are diagnosed, understood, and treated, helping close important gaps in women's healthcare.

Read More:Healthtech Startup RapidPulse Scores $48M in Series B Funding